Immunogenic and protective potentials of recombinant receptor binding domain and a C-terminal fragment of Clostridium botulinum neurotoxin type E

Iranian Journal of Biotechnology

Volumn 9, Issue 3, 2011, Pages 181-187

  Gargari, Seyed Latif Mousavi ^a   Rasooli, Iraj ^a   Valipour, Ebrahim ^b   Basiri, Mohsen ^a   Nazarian, Shahram ^c   Amani, Jafar ^d   Farhadi, Nima ^c  

^a SHAHED UNIVERSITY   (Iran)

^b UNIVERSITY OF ZANJAN   (Iran)

^c IMAM HOSSEIN UNIVERSITY   (Iran)

^d BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Binding Domain; Botulinum Neurotoxin; Recombinant Vaccine; Synthetic Gene

Indexed keywords

BOTULINUM TOXIN E; GANGLIOSIDE; NITRILOTRIACETATE NICKEL; PHOSPHATE BUFFERED SALINE; RECOMBINANT PROTEIN; RECOMBINANT RECEPTOR; SYNAPTOTAGMIN II;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL CELL; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EXPRESSION VECTOR; IMMUNOGENICITY; LETHAL DOSE; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PURIFICATION;

CLOSTRIDIUM BOTULINUM; MUS;

EID: 79959493017     PISSN: 17283043     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Adelson RT (2007). Botulinum neurotoxins: fundamentals for the facial plastic surgeon. Am J Otolaryngol. 28: 260-266.
2. Arimitsu H, Lee JC, Sakaguchi Y, Hayakawa Y, Hayashi M, Nakaura M, Takai H, Lin SN, Mukamoto M, Murphy T, Oguma K (2004). Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum Type C and D neurotoxins. Clin Diagn Lab Immunol. 11: 496-502.
3. Atassi MZ, Dolimbek BZ, Hayakari M, Middlebrook JL, Whitney B, Oshima M (1996). Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species. J Protein Chem. 15: 691-700.
4. Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, Barbieri JT (2008). Subunit vaccine against the seven serotypes of botulism. Infect Immun. 76: 1314-1318.
5. Binz T, Rummel A (2009). Cell entry strategy of clostridial neurotoxins. J Neurochem. 109: 1584-1595.
6. Boles J, West M, Montgomery V, Tammariello R, Pitt ML, Gibbs P,Smith L,LeClaire RD (2006). Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon. 47: 877-884.
7. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72: 248-254.
8. Byrne MP, Smith LA (2000). Development of vaccines for prevention of botulism. Biochimie. 82: 955-966.
9. Byrne MP, Titball RW, Holley J, Smith LA (2000). Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr Purif. 18: 327-337.
10. Clayton MA, Clayton JM, Brown DR, Middlebrook JL (1995). Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun. 63: 2738- 2742.
11. Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ (2007). Mapping of the regions on the heavy chain of botulinum neurotoxin A(BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 44: 1029-1041.
12. Dolimbek BZ, Steward LE, Aoki KR, Atassi MZ (2008). Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin. Mol Immunol. 45: 910- 924.
13. Dong M, Liu H, Tepp WH, Johnson EA, Janz R, Chapman ER (2008). Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell. 19: 5226- 5237.
14. Dux MP, Barent R, Sinha J, Gouthro M, Swanson T, Barthuli A, Inan M, Ross JT, Smith LA,Smith TJ, Webb R, Loveless B,Henderson I, Meagher MM (2006). Purification and scale-up of a recombinant heavy chain fragment C of botulinum neurotoxin serotype E in Pichia pastoris GS115. Protein Expr Purif. 45: 359-367.
15. Holley JL, Elmore M, Mauchline M, Minton N, Titball RW(2000). Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Vaccine. 19: 288-297.
16. Kubota T, Watanabe T, Yokosawa N, Tsuzuki K, Indoh T, Moriishi K, Sanda K, Maki Y, Inoue K, Fujii N (1997). Epitope regions in the heavy chain of Clostridium botulinum type E neurotoxin recognized by monoclonal antibodies. Appl Environ Microbiol. 63: 1214-1218.
17. LaPenotiere HF, Clayton MA, Middlebrook JL (1995). Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Toxicon. 33: 1383-1386.
18. Li L, Singh BR (1998). Isolation of synaptotagmin as a receptor for types A and E botulinum neurotoxin and analysis of their comparative binding using a new microtiter plate assay. J Nat Toxins. 7: 215-226.
19. Mansour AA, Mousavi SL, Rasooli I, Nazarian S, Amani J, Farhadi N (2010). Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E. Biologicals. 38: 260-264.
20. Montecucco C, Schiavo G (1994). Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol. 13: 1-8.
21. Nishiki T, Tokuyama Y, Kamata Y, Nemoto Y, Yoshida A, Sato K, Sekiguchi M, Takahashi M, Kozaki S (1996). The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett. 378: 253-257.
22. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, Shamim M,Gong Y, Simpson LL (2007). Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun. 75: 3043- 3054.
23. Rummel A, Mahrhold S, Bigalke H, Binz T (2004). The HCCdomain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol. 51: 631-643.
24. Rusnak JM, Smith LA (2009). Botulinum neurotoxin vaccines: Past history and recent developments. Hum Vaccin. 5: 794-805.
25. Sharma S, Zhou Y, Singh BR (2006). Cloning, expression, and purification of C-terminal quarter of the heavy chain of botulinum neurotoxin type A. Protein Expr Purif. 45: 288-295.
26. Smith LA (1998). Development of recombinant vaccines for botulinum neurotoxin. Toxicon. 36: 1539-1548.
27. Smith LA, Jensen MJ, Montgomery VA, Brown DR, Ahmed SA, Smith TJ (2004). Roads from vaccines to therapies. Mov Disord. 19 Suppl 8: S48-S52.
28. Tavallaie M, Chenal A, Gillet D, Pereira Y, Manich M, Gibert M, Raffestin S, Popoff MR, Marvaud JC (2004). Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett. 572: 299-306.
29. Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, Smith LA (2007). Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 25: 4273-4282.
30. Woodward LA, Arimitsu H, Hirst R, Oguma K (2003). Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice. Infect Immun. 71: 2941-2944.
31. Yu YZ, Sun ZW, Wang S, Yu WY(2007). High-level expression of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen. Sheng Wu Gong Cheng Xue Bao. 23: 812-817.